Asset Details
Do you wish to reserve the book?
Validation of the new consensus criteria for the diagnosis of corticobasal degeneration
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Validation of the new consensus criteria for the diagnosis of corticobasal degeneration
Do you wish to request the book?
Validation of the new consensus criteria for the diagnosis of corticobasal degeneration
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Validation of the new consensus criteria for the diagnosis of corticobasal degeneration
2014
Overview
Background Corticobasal degeneration (CBD) is a complex neurodegenerative disorder. Accurate diagnosis is increasingly important, with the advent of clinical trials of drugs aimed at modifying the underlying tau pathology. CBD often presents with a ‘corticobasal syndrome’ including impairments of movement and cognition. However, patients with similar corticobasal syndromes can have neurodegenerative pathologies that are not CBD. In addition, patients with CBD may present with aphasia or behavioural change. The clinical diversity of CBD and mimicry by non-CBD pathologies hinders accurate diagnosis. Methods We applied the new consensus criteria of Armstrong and colleagues et al 1 to a cohort of patients with detailed longitudinal clinical evaluation and neuropathology. Results In patients with pathologically confirmed CBD, accuracy of diagnosis was similar under the new and previous criteria: 9/19 (47%) met criteria for probable CBD at presentation, 13/19 (68%) at last clinical assessment. Patients with a corticobasal syndrome but without CBD pathology all (14/14) met the new diagnostic criteria of probable or possible CBD, demonstrating that the new criteria lacks the necessary specificity for an accurate ante mortem clinical diagnosis of CBD. None of the clinical features used in the new criteria were more common in the patients with CBD pathology (n=19) than without (n=14). Conclusions The Armstrong criteria usefully broadens the recognised clinical phenotype of CBD but does not sufficiently improve the specificity of diagnosis to increase the power of clinical trials or targeted applications of tau-based disease-modifying therapies. Further work is required to show whether biomarkers could be more effective than clinical signs in the diagnosis of CBD.
Publisher
BMJ Publishing Group LTD,BMJ Publishing Group
Subject
/ Aged
/ Aphasia
/ Basal Ganglia Diseases - diagnosis
/ Basal Ganglia Diseases - pathology
/ Basal Ganglia Diseases - psychology
/ Consensus Statements as Topic
/ Dementia
/ Female
/ Humans
/ Male
/ Mutation
/ Neurodegenerative Diseases - diagnosis
/ Neurodegenerative Diseases - pathology
/ Neurodegenerative Diseases - psychology
